Pembrolizumab/Axitinib Combination for mRCC in Further-Line Treatment
Pembrolizumab/axitinib is approved as a first-line treatment for metastatic renal cell carcinoma (mRCC), but its safety and efficacy in later lines of therapy has not been researched. When used as a first-line treatment, the drug combination has demonstrated superior progression free survival (PFS), objective response rate (ORR), and overall survival compared with sunitinib. ...
Advertisement
Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Dustin SamplesASCO GU Symposium 2023 | February 1, 2023
Get recommendations for sightseeing, dining, entertainment, and more while you're in town for the conference.
Read More
Zachary BessetteASCO GU Symposium 2023 | January 19, 2023
Norman E Sharpless, MD, University of North Carolina School of Medicine, will present the keynote session.
Zachary BessetteASCO GU Symposium 2023 | January 19, 2023
Attendees will learn about different ways of managing renal cell carcinoma at all stages from research to practice.
Zachary BessetteASCO GU Symposium 2023 | January 19, 2023
Gerhardt Attard, MD, PhD, FRCP, will kick off the event with a session on advanced prostate cancer.

Video Insights

Clinical discussions with experts in the field